Evoke Pharma Q2 2024 Earnings Report

Evoke Pharma EPS Results

• Actual EPS: -$0.93
• Consensus EPS: -$0.72
• Beat/Miss: Missed by -$0.21
• One Year Ago EPS: N/A

Evoke Pharma Revenue Results

• Actual Revenue: $2.55 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Evoke Pharma Announcement Details

• Quarter: Q2 2024
• Date: 8/13/2024
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 13, 2024
• Conference Call Time: 7:00AM ET

Evoke Pharma (NASDAQ:EVOK) is a clinical-stage specialty pharmaceutical company focused on developing novel therapies for gastrointestinal (GI) motility disorders. The company’s lead product candidate, relamorelin, is a selective ghrelin receptor agonist designed to restore gastric motility and accelerate gastric emptying in conditions such as diabetic gastroparesis. Relamorelin has been granted orphan drug designation by the U.S. Food and Drug Administration and has demonstrated proof-of-concept activity in multiple clinical trials, positioning it as a promising treatment for patients with impaired GI function.

In addition to relamorelin, Evoke Pharma is advancing earlier-stage programs targeting metabolic and GI conditions, leveraging its expertise in peptide chemistry and receptor pharmacology. The company’s research efforts aim to extend the therapeutic potential of ghrelin receptor modulation into related indications, including postoperative ileus and chronic constipation. Evoke collaborates with academic and industry partners to optimize its pipeline and expand clinical development into new patient populations.

Founded in 2006 and headquartered in San Diego, California, Evoke Pharma completed its initial public offering on the Nasdaq under the ticker EVOK. The company serves patients across the United States and is exploring opportunities to establish international partnerships for broader market access. Evoke’s leadership team combines decades of experience in gastroenterology drug development, regulatory affairs and commercial strategy to advance its mission of improving quality of life for individuals with debilitating GI disorders.